EmeraMed   Report issue

For profit Phase 2 Phase 3
Founded: Dublin Ireland (2007)

Organization Overview

First Clinical Trial
2015
NCT02486289
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

EmeraMed

Active Ingredients

Drugs in Phase 3 Trials (1)

BDTH2 (1 trial)

Drugs in Phase 2 Trials (1)

emeramide (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

beta-Thalassemia (Phase 2)

Bronchitis (Phase 2)

Mercury Poisoning (Phase 3)

Poisoning (Phase 3)

Thalassemia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 2